Literature DB >> 31292202

CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP.

Casey J Moure1,2, Bill H Diplas1,2, Lee H Chen1,2, Rui Yang1,2, Christopher J Pirozzi1,2, Zhaohui Wang1,2, Ivan Spasojevic3, Matthew S Waitkus1,2, Yiping He4,2, Hai Yan4,2.   

Abstract

Mutations in isocitrate dehydrogenases 1 and 2 (IDH) occur in the majority of World Health Organization grade II and III gliomas. IDH1/2 active site mutations confer a neomorphic enzyme activity producing the oncometabolite D-2-hydroxyglutarate (D-2HG), which generates the glioma CpG island methylation phenotype (G-CIMP). While IDH1/2 mutations and G-CIMP are commonly retained during tumor recurrence, recent work has uncovered losses of the IDH1 mutation in a subset of secondary glioblastomas. Cooccurrence of the loss of the mutant allele with extensive methylation changes suggests a possible link between the two phenomena. Here, we utilize patient-derived IDH1R132H/WT glioma cell lines and CRISPR-Cas9-mediated gene knockout to model the genetic loss of IDH1 R132H, and characterize the effects of this deletion on DNA methylation. After D-2HG production has been abolished by deletions within the IDH1 alleles, these models show persistent DNA hypermethylation at seven CpG sites previously used to define G-CIMP-positivity in patient tumor samples. Despite these defining G-CIMP sites showing persistent hypermethylation, we observed a genome-wide pattern of DNA demethylation, enriched for CpG sites located within open sea regions of the genome, as well as in CpG-island shores of transcription start sites, after loss of D-2HG production. These results suggest that inhibition of D-2HG from genetic deletion of IDH alleles is not sufficient to reverse hypermethylation of all G-CIMP-defining CpG sites, but does result in more demethylation globally and may contribute to the formation of a G-CIMP-low-like phenotype. IMPLICATIONS: These findings show that loss of the IDH1 mutation in malignant glioma cells leads to a pattern of DNA methylation alterations, and shows plausibility of IDH1 mutation loss being causally related to the gain of a G-CIMP-low-like phenotype. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31292202      PMCID: PMC6774824          DOI: 10.1158/1541-7786.MCR-19-0309

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  34 in total

1.  Spontaneous loss of heterozygosity leading to homozygous R132H in a patient-derived IDH1 mutant cell line.

Authors:  H Artee Luchman; Charles Chesnelong; J Gregory Cairncross; Samuel Weiss
Journal:  Neuro Oncol       Date:  2013-06-11       Impact factor: 12.300

2.  Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays.

Authors:  Martin J Aryee; Andrew E Jaffe; Hector Corrada-Bravo; Christine Ladd-Acosta; Andrew P Feinberg; Kasper D Hansen; Rafael A Irizarry
Journal:  Bioinformatics       Date:  2014-01-28       Impact factor: 6.937

3.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.

Authors:  Houtan Noushmehr; Daniel J Weisenberger; Kristin Diefes; Heidi S Phillips; Kanan Pujara; Benjamin P Berman; Fei Pan; Christopher E Pelloski; Erik P Sulman; Krishna P Bhat; Roel G W Verhaak; Katherine A Hoadley; D Neil Hayes; Charles M Perou; Heather K Schmidt; Li Ding; Richard K Wilson; David Van Den Berg; Hui Shen; Henrik Bengtsson; Pierre Neuvial; Leslie M Cope; Jonathan Buckley; James G Herman; Stephen B Baylin; Peter W Laird; Kenneth Aldape
Journal:  Cancer Cell       Date:  2010-04-15       Impact factor: 31.743

4.  De novo identification of differentially methylated regions in the human genome.

Authors:  Timothy J Peters; Michael J Buckley; Aaron L Statham; Ruth Pidsley; Katherine Samaras; Reginald V Lord; Susan J Clark; Peter L Molloy
Journal:  Epigenetics Chromatin       Date:  2015-01-27       Impact factor: 4.954

5.  The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma.

Authors:  Bill H Diplas; Xujun He; Jacqueline A Brosnan-Cashman; Heng Liu; Lee H Chen; Zhaohui Wang; Casey J Moure; Patrick J Killela; Daniel B Loriaux; Eric S Lipp; Paula K Greer; Rui Yang; Anthony J Rizzo; Fausto J Rodriguez; Allan H Friedman; Henry S Friedman; Sizhen Wang; Yiping He; Roger E McLendon; Darell D Bigner; Yuchen Jiao; Matthew S Waitkus; Alan K Meeker; Hai Yan
Journal:  Nat Commun       Date:  2018-05-25       Impact factor: 14.919

6.  DNA demethylation is associated with malignant progression of lower-grade gliomas.

Authors:  Masashi Nomura; Kuniaki Saito; Koki Aihara; Genta Nagae; Shogo Yamamoto; Kenji Tatsuno; Hiroki Ueda; Shiro Fukuda; Takayoshi Umeda; Shota Tanaka; Shunsaku Takayanagi; Ryohei Otani; Takahide Nejo; Taijun Hana; Satoshi Takahashi; Yosuke Kitagawa; Mayu Omata; Fumi Higuchi; Taishi Nakamura; Yoshihiro Muragaki; Yoshitaka Narita; Motoo Nagane; Ryo Nishikawa; Keisuke Ueki; Nobuhito Saito; Hiroyuki Aburatani; Akitake Mukasa
Journal:  Sci Rep       Date:  2019-02-13       Impact factor: 4.379

7.  A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data.

Authors:  Andrew E Teschendorff; Francesco Marabita; Matthias Lechner; Thomas Bartlett; Jesper Tegner; David Gomez-Cabrero; Stephan Beck
Journal:  Bioinformatics       Date:  2012-11-21       Impact factor: 6.937

8.  Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas.

Authors:  Liwei Zhang; Lee H Chen; Hong Wan; Rui Yang; Zhaohui Wang; Jie Feng; Shaohua Yang; Siân Jones; Sizhen Wang; Weixin Zhou; Huishan Zhu; Patrick J Killela; Junting Zhang; Zhen Wu; Guilin Li; Shuyu Hao; Yu Wang; Joseph B Webb; Henry S Friedman; Allan H Friedman; Roger E McLendon; Yiping He; Zachary J Reitman; Darell D Bigner; Hai Yan
Journal:  Nat Genet       Date:  2014-06-01       Impact factor: 38.330

9.  Insulator dysfunction and oncogene activation in IDH mutant gliomas.

Authors:  William A Flavahan; Yotam Drier; Brian B Liau; Shawn M Gillespie; Andrew S Venteicher; Anat O Stemmer-Rachamimov; Mario L Suvà; Bradley E Bernstein
Journal:  Nature       Date:  2015-12-23       Impact factor: 49.962

10.  A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence.

Authors:  Camila Ferreira de Souza; Thais S Sabedot; Tathiane M Malta; Lindsay Stetson; Olena Morozova; Artem Sokolov; Peter W Laird; Maciej Wiznerowicz; Antonio Iavarone; James Snyder; Ana deCarvalho; Zachary Sanborn; Kerrie L McDonald; William A Friedman; Daniela Tirapelli; Laila Poisson; Tom Mikkelsen; Carlos G Carlotti; Steven Kalkanis; Jean Zenklusen; Sofie R Salama; Jill S Barnholtz-Sloan; Houtan Noushmehr
Journal:  Cell Rep       Date:  2018-04-10       Impact factor: 9.423

View more
  10 in total

1.  Mutant IDH Inhibits IFNγ-TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma.

Authors:  Meng-Ju Wu; Lei Shi; Juan Dubrot; Joshua Merritt; Vindhya Vijay; Ting-Yu Wei; Emily Kessler; Kira E Olander; Ramzi Adil; Amaya Pankaj; Krishna Seshu Tummala; Vajira Weeresekara; Yuanli Zhen; Qibiao Wu; Meiqi Luo; William Shen; María García-Beccaria; Mirian Fernández-Vaquero; Christine Hudson; Sebastien Ronseaux; Yi Sun; Rodrigo Saad-Berreta; Russell W Jenkins; Tong Wang; Mathias Heikenwälder; Cristina R Ferrone; Lipika Goyal; Brandon Nicolay; Vikram Deshpande; Rahul M Kohli; Hongwu Zheng; Robert T Manguso; Nabeel Bardeesy
Journal:  Cancer Discov       Date:  2022-03-01       Impact factor: 38.272

2.  SLC1A1-mediated cellular and mitochondrial influx of R-2-hydroxyglutarate in vascular endothelial cells promotes tumor angiogenesis in IDH1-mutant solid tumors.

Authors:  Xiaomin Wang; Ziqi Chen; Jun Xu; Shuai Tang; Nan An; Lei Jiang; Yixiang Zhang; Shaoying Zhang; Qingli Zhang; Yanyan Shen; Shijie Chen; Xiaojing Lan; Ting Wang; Linhui Zhai; Siyuwei Cao; Siqi Guo; Yingluo Liu; Aiwei Bi; Yuehong Chen; Xiameng Gai; Yichen Duan; Ying Zheng; Yixian Fu; Yize Li; Liang Yuan; Linjiang Tong; Kun Mo; Mingcheng Wang; Shu-Hai Lin; Minjia Tan; Cheng Luo; Yi Chen; Jia Liu; Qiansen Zhang; Leping Li; Min Huang
Journal:  Cell Res       Date:  2022-04-22       Impact factor: 46.297

3.  Patient-derived cells from recurrent tumors that model the evolution of IDH-mutant glioma.

Authors:  Lindsey E Jones; Stephanie Hilz; Matthew R Grimmer; Tali Mazor; Chloé Najac; Joydeep Mukherjee; Andrew McKinney; Tracy Chow; Russell O Pieper; Sabrina M Ronen; Susan M Chang; Joanna J Phillips; Joseph F Costello
Journal:  Neurooncol Adv       Date:  2020-07-16

4.  Comparison of Global DNA Methylation Patterns in Human Melanoma Tissues and Their Derivative Cell Lines.

Authors:  Euan J Rodger; Suzan N Almomani; Jackie L Ludgate; Peter A Stockwell; Bruce C Baguley; Michael R Eccles; Aniruddha Chatterjee
Journal:  Cancers (Basel)       Date:  2021-04-28       Impact factor: 6.639

Review 5.  Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-Mutations.

Authors:  Pasquale Persico; Elena Lorenzi; Agnese Losurdo; Angelo Dipasquale; Antonio Di Muzio; Pierina Navarria; Federico Pessina; Letterio Salvatore Politi; Giuseppe Lombardi; Armando Santoro; Matteo Simonelli
Journal:  Cancers (Basel)       Date:  2022-02-22       Impact factor: 6.639

Review 6.  Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations.

Authors:  Ingvild Comfort Hvinden; Tom Cadoux-Hudson; Christopher J Schofield; James S O McCullagh
Journal:  Cell Rep Med       Date:  2021-12-21

7.  R132H IDH1 sensitizes glioma to the antiproliferative and cytotoxic effects of BET inhibition.

Authors:  Thomas K Sears; Kevin D Woolard
Journal:  J Cancer Res Clin Oncol       Date:  2022-04-25       Impact factor: 4.322

8.  CIMP-positive glioma is associated with better prognosis: A systematic analysis.

Authors:  Yingying Xu; Huashi Xiao; Wenqing Hu; He-Chun Shen; Wanjun Liu; Siyuan Tan; Chuanli Ren; Xiaomin Zhang; Xishuai Yang; Guo Yu; Ting Yang; Duonan Yu; Liang Zong
Journal:  Medicine (Baltimore)       Date:  2022-09-30       Impact factor: 1.817

Review 9.  Epigenetic Reprogramming for Targeting IDH-Mutant Malignant Gliomas.

Authors:  Jong-Whi Park; Şevin Turcan
Journal:  Cancers (Basel)       Date:  2019-10-22       Impact factor: 6.639

10.  IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat.

Authors:  Thomas K Sears; Craig M Horbinski; Kevin D Woolard
Journal:  J Neurooncol       Date:  2021-08-23       Impact factor: 4.130

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.